Physician profile
Anthony D Davis
NPI 1962446898
$18,662.24
in general payments reported to CMS, 2019-2025
60 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,665 · 2020: $4,268 · 2021: $1,882 · 2022: $1,657 · 2023: $4,903 · 2024: $1,643 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,215 · Consulting Fee: $2,835 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,215.24 |
| Consulting Fee | $2,835.00 |
| Education | $141.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,871.15 | 2019-2025 | |
| Amgen INC. | $3,658.39 | 2019-2025 | Prolia, Repatha, Evenity |
| Novo Nordisk INC | $1,102.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $830.77 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.73 | 2019-2025 | Jardiance |
| Abbvie INC. | $710.44 | 2019-2025 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $704.99 | 2021-2025 | |
| Amarin Pharma, INC. | $648.61 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $592.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $562.60 | 2019-2024 | Farxiga, Fasenra, Breztri |
| Kowa Pharmaceuticals America, INC. | $457.18 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Teva Pharmaceuticals USA, INC. | $386.34 | 2022-2024 | Austedo Xr, Austedo |
| Medicure Pharma INC. | $301.57 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.21 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $207.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.